BioArctic AB (publ) announced that the Ministry of Food and Drug Safety (MFDS) in South Korea published that Leqembi® (lecanemab) has been approved for treatment in patients with mild cognitive impairment due to Alzheimer's disease (AD) and mild AD (early AD).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
226.6 SEK | +0.18% |
|
-4.63% | -15.38% |
Jun. 10 | Global markets live: ABB, Roche, Microsoft, Apple, Tesla... | ![]() |
Jun. 10 | BioArctic Reports US FDA's Acceptance of Biologics License Application for Leqembi IV Maintenance Dosing | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.38% | 1.9B | |
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- BIOA B Stock
- News BioArctic AB
- BioArctic AB Approves Leqembi [®] for the Treatment of Alzheimer's Disease in South Korea